Wakamoto Pharmaceutical Co., Ltd. (JP:4512)

:4512

4512

Wakamoto Pharmaceutical Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4512 full AI Analyst Report?

Wakamoto Pharmaceutical Co., Ltd. (4512) Price & Analysis

0 Followers

4512 Stock Chart & Stats

¥286.00

-¥4.00(-1.79%)

At close: Jan 08 4:00 PM EST

¥286.00

-¥4.00(-1.79%)

Day’s Range― - ―

52-Week Range¥240.00 - ¥380.00

Previous CloseN/A

Volume100.70K

Average Volume (3M)65.94K

Market Cap

¥8.92B

Enterprise Value¥7.24B

Total Cash (Recent Filing)¥3.56B

Total Debt (Recent Filing)¥100.00M

Price to Earnings (P/E)39.2

Beta0.43

Next Earnings

Jul 31, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.06%

Share Statistics

EPS (TTM)-5.12

Shares Outstanding34,838,326

10 Day Avg. Volume55,010

30 Day Avg. Volume65,936

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)1.01

Price to Sales (P/S)1.23

P/FCF Ratio-11.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetThe company’s very low leverage and sizable equity base materially reduce refinancing and solvency risk. This conservative financing provides durable flexibility to fund R&D, absorb demand shocks, or pursue opportunistic investments without requiring near-term external debt, supporting long-term strategy execution.

Strong Revenue GrowthSustained ~27% top-line growth reflects durable demand or improved commercialization in core digestive/intestinal products. Persistent revenue expansion enhances scale economics, supports operating leverage, and improves the odds of converting higher gross profits into stronger sustainable operating profits and cash generation over months.

Healthy Gross MarginsGross margins in the high-40% range indicate structural pricing power or efficient production economics in its product lines. High gross margins provide a lasting cushion to absorb SG&A and R&D spending and offer a clear pathway for net margin improvement if sales scale and operating leverage persist.

Bears Say

Negative Operating Cash FlowThree straight years of negative operating and free cash flow, including roughly -¥1.05B most recently, indicate a structural cash-generation shortfall. Persistent negative cash flow limits the firm’s ability to self-fund growth, dividends or capex and increases reliance on reserves or external financing despite low leverage.

Thin Net MarginsNet margins around 2% offer minimal buffer against cost inflation or pricing pressure. Such thin profitability constrains retained earnings growth and return on equity, meaning the company struggles to convert its strong capital base into meaningful, durable shareholder returns absent sustained margin expansion.

Earnings VolatilityHistoric swings—including a loss in 2021 and negative EBIT in 2024–2025—signal execution and demand volatility. This undermines predictability for planning and capital allocation, raises the probability of future earnings setbacks, and complicates efforts to steadily improve cash flow and investor returns.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥240.00 and its highest was ¥380.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥8.92B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is Jul 31, 2026 which is in 35 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥0.35 earnings per share for the quarter, beating the consensus estimate of N/A by ¥0.35.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3.473 which represents an annual dividend yield of 1.06%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥0.35 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.734%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.